She consulted the rheumatology department for consideration of 30 mg/day PSL, but was bio-switched to the IL-6 inhibitor sarilumab (SAR) in June Y+2 due to the high risk of infection and a history of synovitis and psoriasis induced by TNF inhibitors. This evidence concerns the gene IL6 and psoriasis.